Format

Send to

Choose Destination
ACS Infect Dis. 2018 Jul 13;4(7):1041-1047. doi: 10.1021/acsinfecdis.8b00112. Epub 2018 May 17.

The Therapeutic Pipeline for Pseudomonas aeruginosa Infections.

Author information

1
Department of Biochemistry & Biomedical Sciences and the Michael G. DeGroote Institute for Infectious Diseases Research , McMaster University , 4H18 Health Sciences Centre, 1280 Main Street West , Hamilton , Ontario L8S 4K1 , Canada.

Abstract

Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen, designated by the World Health Organization as a critical priority for development of new therapeutics due to high levels of intrinsic and acquired antibiotic resistance. Other challenges include its versatility (it can persist in the environment and most strains are capable of causing disease in compromised hosts), robust efflux mechanisms that limit drug penetration, and the propensity to form antimicrobial-tolerant biofilms. Novel therapeutics in development to prevent or treat P. aeruginosa infections include vaccines, biologics such as antimicrobial peptides and therapeutic antibodies, virulence inhibitors, antimicrobials with novel targets, antibody-drug conjugates, resistance inhibitor-antibiotic or antibiotic-potentiator combinations, and bacteriophages or phage-derived lysins.

Supplemental Content

Loading ...
Support Center